Multimer Detection System-Oligomerized Amyloid Beta (MDS-OAβ): A Plasma-Based Biomarker Differentiates Alzheimer's Disease from Other Etiologies of Dementia.

Autor:	Dominguez, Jacqueline Cotoong, Yu, Jeryl Ritzi Tan, De Guzman, Ma Fe, Ampil, Encarnita, Guevarra, Anne Cristine, Joson, Ma. Lourdes, Reandelar Jr., Macario, Martinez, Ma. Socorro, Ligsay, Antonio, Ocampo, Ferron, Kim, SangYun
Předmět:	ALZHEIMER'S disease diagnosis BIOMARKERS VASCULAR dementia STATISTICS ALZHEIMER'S disease ANALYSIS of variance ONE-way analysis of variance AMYLOID beta-protein precursor ENZYME-linked immunosorbent assay CHI-squared test DATA analysis software DATA analysis SPECTROPHOTOMETRY
Zdroj:	International Journal of Alzheimer's Disease; 5/2/2022, p1-6, 6p
Abstrakt:	With emerging amyloid therapies, documentation of the patient's amyloid status to confirm the etiology of a clinical diagnosis is warranted prior to instituting amyloid-based therapy. The Multimer Detection System-Oligomeric Amyloid-β (MDS-OAβ) is a noninvasive blood-based biomarker utilized to measure Aβ oligomerization tendency. We determined the difference in MDS-OAβ ratio across the groups: (a) no cognitive impairment or subjective cognitive impairment (NCI/SCI), (b) Alzheimer's disease (AD), (c) non-AD, and (d) mixed Alzheimer's disease-Vascular dementia (AD-VaD). MDS-OAβ level was not significantly different between AD and mixed AD-VaD, but both groups were significantly different from the NCI/SCI and from the non-AD group. An MDS-OAβ level of >1 could potentially indicate clinical variants of AD or mixed pathology (AD-VaD). [ABSTRACT FROM AUTHOR]
Databáze:	Complementary Index
Externí odkaz:	Zobrazit plný text záznamu Plný text ve formátu HTML
Nepřihlášeným uživatelům se plný text nezobrazuje	K zobrazení výsledku je třeba se přihlásit.